

The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2024, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS		
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS	
Antimigraine Agents, Prophylaxis	Emgality 120mg Syringe and Pen (galcanezumab-gnlm)	
Antipsychotics- Injectable, Atypicals	Abilify Asimtufii (aripiprazole)	
Antipsychotics- Injectable, Atypicals	Uzedy (risperidone)	
Antipsychotics- Oral	Vraylar (cariprazine)	
Muscular Dystrophy Agents	Emflaza (deflazacort)	
Opiate Dependence Treatments	Zimhi (naloxone HCl injection)	

NEW NON-PREFERRED DRUGS		
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS	
Antineoplastics – Selected Systemic Enzyme Inhibitors	Akeega (niraparib / abiraterone)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	Vanflyta (quizartinib)	
Antiretrovirals	Cimduo (lamivudine / tenofovir DF)	
Antiretrovirals	Juluca (dolutegravir / rilpivirine)	
Cytokine & CAM Antagonists	Cyltezo (adalimumab-adbm)	
Cytokine & CAM Antagonists	Hadlima (adalimumab-bwwd)	
Cytokine & CAM Antagonists	Hulio (adalimumab-fkjp)	
Cytokine & CAM Antagonists	Hyrimoz (adalimumab-adaz)	
Cytokine & CAM Antagonists	Idacio (adalimumab-aacf)	
Cytokine & CAM Antagonists	Litfulo (ritlecitinib)	
Cytokine & CAM Antagonists	Yuflyma (adalimumab-aaty)	
Cytokine & CAM Antagonists	Yusimry (adalimumab-aqvh)	
Growth Hormone	Ngenla (somatrogon-ghla)	



NEW NON-PREFERRED DRUGS		
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS	
Hypoglycemics, SGLT2 Inhibitors	Inpefa (sotagliflozin)	
IBS / SBS / Selected GI Agents	Movantik (naloxegol)	
Ophthalmic, Dry Eye Agents	Miebo (perfluorohexyloctane)	
Ophthalmic, Glaucoma Agents	lyuzeh (lantanoprost)	
Opiate Dependence Treatments	Brixadi (buprenorphine)	
Opiate Dependence Treatments	Kloxxado (naloxone)	
Opiate Dependence Treatments	Opvee (nalmefene)	
Select Contraceptive Products	Phexxi (lactic acid, citric acid, and potassium bitartrate)	